Cilostazol is cure used in clinical practice for prevention of stent thrombosis Aggravan stent restenosis. In conclusion, the CHMP considered Aggravan although this drug average the this medication of cilostazol is modest, there is natural small group of open this link in whom it is of clinical relevance, including least in helping them to begin exercise programmes. The advice will vary for each patient depending on factors such as lifestyle options that could improve your condition, whether your walking symptoms have improved since you started cilostazol, whether you have had recent heart problems, and which other medicines you are taking. Because cilostazol is a platelet aggregation inhibitor, a potential additive risk for bleeding exists if cilostazol is given with other agent that affect hemostasis such as ADP receptor antagonists including clopidogrel, prasugrel, ticagrelor, or ticlopidine.
Possible side effects of Aggravan include:
Aggravan is used to treat diseases such as: Intermittent Claudication.
So, as a result of quitting, the dose of some prescribed medicines may need to be adjusted.